If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
ZypAdhera Summary of Product Characteristics (SmPC)
ZypAdhera® (olanzapine pamoate): Half-life and Elimination
The half-life of olanzapine after olanzapine pamoate is 30 days compared to 30 hours following oral administration. the absorption and elimination are complete approximately six to eight months after the last injection.
a single intramuscular injection with olanzapine pamoate, the slow
dissolution of the olanzapine pamoate salt in muscle tissue begins
immediately and provides a slow continuous release of olanzapine for
more than four weeks.1
release becomes diminishingly smaller within eight to twelve weeks.1
absorption and elimination are complete approximately six to eight
months after the last injection.1
combination of the release profile and the dosage regimen
(intramuscular injection every two or four weeks) result in sustained
olanzapine plasma concentrations. Plasma concentrations remain
measurable for several months after each olanzapine pamoate
plasma clearance after oral olanzapine is lower in females (18.9
l/hr) versus males (27.3 l/hr), and in non-smokers (18.6 l/hr) versus
smokers (27.7 l/hr). Similar pharmacokinetic differences between
males and females and smokers and non-smokers were observed in
olanzapine pamoate clinical trials. However, the magnitude of the
impact of gender, or smoking on olanzapine clearance is small in
comparison to the overall variability between individuals.1
full information please refer to summary of product characteristics.
ZypAdhera [summary of product characteristics] Eli Lilly Netherland
B.V., The Netherlands.
Date of Last Review:April 12, 2018
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org